Abstract

Medications which are derived by combining one or more doses of the agonist, vitamin K, with doses of one or more selected vitamin K antagonists such as the R-isomer of warfarin, the R-isomer of phenprocoumon, or the racemic phenprocoumon are useful in anticoagulant therapy. These products are designed to minimize or circumvent the detrimental impact of newly identified genetic-based variables that currently significantly complicate the therapeutic response of individual patients to anticoagulation therapy.


Claims
Download PDF
Document Preview
Document History
  • Publication: Jul 10, 2008
  • Application: Dec 18, 2007
    WO US 2007/0025889 W
  • Priority: Dec 19, 2006
    US US 87571506 P

Sign in to the Lens

Feedback